The vaccine, if approved, would be the first available for protecting infants from a pathogen that each year kills hundreds of young children. It is one of a recent wave of drugmaker successes against the disease after decades of effort. The U.S. approved the first vaccine for RSV for use in older adults earlier this month and could soon approve a long-acting antibody for RSV in babies that Europe cleared in November.
